Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00811889 · ClinicalTrials.gov registry record · Phase 2

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

A Phase 2 study of Type 2 Diabetes and Chronic Kidney Disease, sponsored by Biogen.

Completed
Registry status
Phase 2
Development phase
227
Enrollment target
20
Study locations

NCT00811889: Completed Phase 2 study of Type 2 Diabetes and Chronic Kidney Disease, sponsored by Biogen.

NCT00811889 is a Phase 2 study of Type 2 Diabetes and Chronic Kidney Disease that has completed, run by Biogen. The registered enrollment target is 227 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00811889, a Phase 2 study of Type 2 Diabetes and Chronic Kidney Disease, has completed, sponsored by Biogen.

COMPLETED
Registry status
Phase 2
Development phase
227 participants
Enrollment target
20
Study locations

Study Summary

This study assesses the effects of bardoxolone methyl (RTA 402) in patients with type 2 diabetes and chronic kidney disease.

Conditions Studied

Type 2 Diabetes Chronic Kidney Disease Diabetic Nephropathy

Interventions

  • OTHER Placebo
  • DRUG Bardoxolone Methyl (RTA 402)

Study Locations (20)

California

  • - Chula Vista
  • - La Mesa
  • - Mission Viejo
  • - Orange
  • - Riverside
  • - San Dimas

Florida

  • - Brandon
  • - Miami
  • - Pembroke Pines
  • - Port Charlotte
  • - West Palm Beach

Alabama

  • - Birmingham
  • - Montgomery

Illinois

  • - Chicago
  • - Peoria

Connecticut

  • - Middlebury

District of Columbia

  • - Washington D.C.

Georgia

  • - Marietta

Louisiana

  • - Baton Rouge

Trial Details

FieldValue
Enrollment Target 227 participants
Start Date 2009-04-30
Est. Completion 2010-12-31
Phase Phase 2
Biogen

334 total trials

What the finished NCT00811889 record still lists

NCT00811889 is an interventional study that assigns participants to a tested intervention. The registered 227 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (94% lower).

The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00811889 names 20 study sites across 9 states, led by California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT00811889 about?

NCT00811889 is a clinical study titled "Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease". This study assesses the effects of bardoxolone methyl (RTA 402) in patients with type 2 diabetes and chronic kidney disease.

What is the current status of trial NCT00811889?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2009-04-30. Estimated completion is 2010-12-31.

What conditions does trial NCT00811889 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Chronic Kidney Disease, Diabetic Nephropathy.

What interventions are being tested in trial NCT00811889?

The interventions under investigation include: Placebo (OTHER), Bardoxolone Methyl (RTA 402) (DRUG).

Who is sponsoring clinical trial NCT00811889?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00811889 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00811889's enrollment target sits among peer trials

227 86th of 327 higher than 241 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04751409 · 227 participants · Phase 2

    Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities

  • NCT05742360 · 227 participants

    Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype

  • NCT05890352 · 227 participants · Phase 2

    Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  • NCT05107908 · 228 participants · NA

    Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT00811889, the US trial registry maintained by the National Library of Medicine. NCT00811889 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.